Discovery of active compounds in Danshen-Chuanxiong formula for blood-brain barrier protection: a multi-parametric study using an OGD/R-induced spheroid model
- PMID: 40782316
- DOI: 10.1007/s11418-025-01939-x
Discovery of active compounds in Danshen-Chuanxiong formula for blood-brain barrier protection: a multi-parametric study using an OGD/R-induced spheroid model
Abstract
Blood-brain barrier (BBB) dysfunction is a well-established pathological phenotype of ischemic stroke, and targeting BBB integrity has emerged as a promising therapeutic strategy. Danshen-Chuanxiong formula (DS-CX), an effective herbal combination against ischemic stroke, has demonstrated regulatory effects on the BBB at various stages of ischemic stroke. However, its specific BBB-protective components and underlying molecular mechanisms remain unclear. Recent advances in multicellular self-assembled BBB spheroids have shown distinct advantages in disease modeling and drug discovery, offering a novel approach to address these questions. To simulate ischemic stroke-induced BBB dysfunction, we developed an oxygen-glucose deprivation/reoxygenation (OGD/R)-induced BBB disruption model using multicellular spheroids. To identify the effective substances of DS-CX responsible for BBB protection, we conducted a multi-parametric evaluation to assess BBB permeability, tight junctions, cell viability, reactive oxygen species (ROS) levels, inflammatory markers, and apoptotic phenotypes using high-content imaging. Further immunofluorescence and transcription analyses were performed to elucidate the BBB-protective mechanisms of DS-CX and its active components. Similar to the overall effects of DS-CX on BBB protection, preliminary screening fortunately found that both protocatechuic acid, ferulic acid, and senkyunolide I significantly reduced OGD/R-induced leakage, and upregulated the protein and mRNA levels of ZO-1 and Claudin-5 in BBB spheroids. Further multi-phenotypic assessments manifested that DS-CX and its active compounds effectively improved cell survival, reduced ROS production, inhibited inflammation, and decreased apoptosis, compared to the damaged BBB spheroids without drug intervention. Molecular experiments showed that DS-CX and its active constituents not only rescued the abnormal protein levels of pivotal targets related to oxidative stress (HO-1), inflammation (MMP-9, TLR-4), and apoptosis (Caspase-3, Bax, Bcl-2) in OGD/R-treated BBB spheroids, but also normalized the dysregulated mRNA levels of vWF, HO-1, MMP-9, TLR-4, TNF-α, IL-6, IL-1β, and IL-18 caused by OGD/R stimulation. Collectively, the present work successfully identified protocatechuic acid, ferulic acid, and senkyunolide I as key BBB-protective components of DS-CX against ischemic stroke. These compounds likely exert their therapeutic effects through multi-target regulation of oxidative stress, inflammation, and apoptosis. Our findings provide a novel spheroid-based multi-parametric screening approach for discovering BBB-targeted therapies in ischemic stroke.
Keywords: 3D spheroid-based disruption model of BBB; Active compounds; BBB protection; Danshen–Chuanxiong formula; Multi-phenotypic and multi-parametric evaluation.
© 2025. The Author(s) under exclusive licence to The Japanese Society of Pharmacognosy.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests regarding the publication of this manuscript.
Similar articles
-
Tirzepatide mitigates Stroke-Induced Blood-Brain barrier disruption by modulating Claudin-1 and C/EBP-α pathways.Mol Med. 2025 Jul 23;31(1):263. doi: 10.1186/s10020-025-01312-4. Mol Med. 2025. PMID: 40702450 Free PMC article.
-
Remote Ischemic Postconditioning Improve Cerebral Ischemia-Reperfusion Injury Induced Cognitive Dysfunction through Suppressing Mitochondrial Apoptosis in Hippocampus via TK/BK/B2R-Mediated PI3K/AKT.Mol Neurobiol. 2025 Aug;62(8):10652-10669. doi: 10.1007/s12035-025-04864-y. Epub 2025 Apr 14. Mol Neurobiol. 2025. PMID: 40229456 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
-
The Protective Effect of Low-dose Nicotine on Ischemia Stroke by Maintaining the Integrity of the Blood-Brain Barrier.Nicotine Tob Res. 2025 Jul 22;27(8):1420-1429. doi: 10.1093/ntr/ntaf034. Nicotine Tob Res. 2025. PMID: 39921606
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
References
-
- Obermeier B, Daneman R, Ransohoff RM (2013) Development, maintenance and disruption of the blood-brain barrier. Nat Med 19(12):1584–1596. https://doi.org/10.1038/nm.3407 - DOI - PubMed - PMC
-
- Nadareishvili Z, Simpkins AN, Hitomi E, Reyes D, Leigh R (2019) Post-stroke blood-brain barrier disruption and poor functional outcome in patients receiving thrombolytic therapy. Cerebrovasc Dis 47(3–4):135–142. https://doi.org/10.1159/000499666 - DOI - PubMed
-
- Sweeney MD, Sagare AP, Zlokovic BV (2018) Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol 14(3):133–150. https://doi.org/10.1038/nrneurol.2017.188 - DOI - PubMed - PMC
-
- Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV (2019) Blood-brain barrier: from physiology to disease and back. Physiol Rev 99(1):21–78. https://doi.org/10.1152/physrev.00050.2017 - DOI - PubMed
-
- Jiang X, Andjelkovic AV, Zhu L, Yang T, Bennett MVL, Chen J, Keep RF, Shi Y (2018) Blood-brain barrier dysfunction and recovery after ischemic stroke. Prog Neurobiol 163:144–171. https://doi.org/10.1016/j.pneurobio.2017.10.001 - DOI - PubMed
Grants and funding
- 82104351/National Natural Science Foundation of China
- 82361138570/National Natural Science Foundation of China
- 2024ZF023/Zhejiang Provincial Traditional Chinese Medicine Science and Technology Project
- LR23H280001/Zhejiang Provincial Natural Science Foundation of China
- 2024C03106/"Pioneer" and "Leading Goose" R&D Program of Zhejiang
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous